Cellectis (ADR)
Develops gene-edited allogeneic CAR-T candidates and manufacturing capabilities.
Something off on this page? Send us feedback.
Profile
Develops donor-derived UCART cell-therapy candidates for blood cancers and applies its TALEN platform in an AstraZeneca collaboration. Its disclosed proprietary focus is lasme-cel for B-cell acute lymphoblastic leukemia and eti-cel for non-Hodgkin lymphoma.
Gene-edits donor-derived T cells into allogeneic UCART candidates for immuno-oncology, supported by TALEN®/nuclease technologies and manufacturing capabilities. The proprietary clinical focus is lasme-cel for relapsed or refractory B-cell acute lymphoblastic leukemia and eti-cel for relapsed or refractory non-Hodgkin lymphoma.
Operations span Paris, New York, and Raleigh, with Paris producing starting materials and Raleigh handling UCART clinical and commercial manufacturing and release testing. Most of the workforce has been in research and development.
Clinical and regulatory progress for lasme-cel and eti-cel shapes the business, alongside the AstraZeneca collaboration, which uses its editing expertise and manufacturing capabilities across oncology, immunology, and rare genetic diseases.
Company facts
Key statistics
Year to date −28.5% · Average volume (30d) 16.7K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| May 28, 2026 | Barclays | Target | $8 | $9 | |
| Oct 20, 2025 | Wells Fargo | Target | $4 | ||
| Oct 17, 2025 | Barclays | Reiterate | Overweight | $8 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | −$0.26 | −$0.22 | +16.3% | $11.0M | $6.9M | −37.5% | +5.58% |
| May 11, 2026Q1 FY26 | −$0.26 | −$0.18 | +30.3% | $11.0M | $7.5M | −31.6% | −0.50% |
| Mar 19, 2026Q4 FY25 | −$0.20 | −$0.26 | −27.9% | $13.4M | $12.2M | −8.9% | −4.02% |
| Nov 7, 2025Q3 FY25 | −$0.10 | $0.01 | +110.0% | $10.3M | $35.2M | +242.4% | +11.29% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $10.7M | $16.7M | $35.2M | $10.4M | $5.8M | $5.2M | |
| Gross profit | $8.6M | $14.3M | $32.8M | $7.4M | $1.2M | $815.9K | |
| Operating income | −$14.2M | −$9.6M | $8.0M | −$17.4M | −$27.1M | −$25.5M | |
| Net income | −$18.1M | −$23.7M | $589.0K | −$26.3M | −$17.8M | −$21.8M | |
| Diluted EPS | −$0.18 | −$0.24 | $0.01 | −$0.27 | −$0.18 | −$0.22 | |
| Gross margin | 81.1% | 85.5% | 93.3% | 71.2% | 21.5% | 15.6% | |
| Operating margin | -133.1% | -57.3% | 22.9% | -166.9% | -467.4% | -487.4% |
Fiscal years (4-quarter sums)FY21 $57.3M · FY22 $19.1M · FY23 $755.0K · FY24 $41.5M · FY25 $72.9M
Revenue by geography · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $166.8M · Total debt $84.6M · Total assets $267.4M · Shareholders' equity $41.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 100.42M · Float 85.65M · 85.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| AstraZeneca Holdings B.V. | 44.00M | 44.00% | 13D | Jan 24, 2025 |
| Caisse des Depots | 10.60M | 11.10% | 13D | Dec 12, 2025 |
| B Group, Inc. | 3.28M | 3.27% | 13F | May 15, 2026 |
| UBS Asset Management Americas Inc | 3.18M | 3.17% | 13F | May 13, 2026 |
| Long Focus Capital Management, LLC | 2.74M | 2.73% | 13F | May 15, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Gilead Sciences
Marketed CD19 CAR-T options in adult B-ALL and B-cell lymphoma
- Autolus Therapeutics (ADR)
Approved CD19 CAR-T for adult relapsed/refractory B-cell precursor ALL
- Bristol-Myers Squibb
Marketed CD19 CAR-T for adult relapsed/refractory large B-cell lymphoma
- Novartis (ADR)
Approved CD19 CAR-T in B-ALL and relapsed/refractory B-cell lymphoma
- Caribou Biosciences
Allogeneic CD19 CAR-T in clinical development for r/r B-cell NHL
- CRISPR Therapeutics
Allogeneic CD19 CAR-T in clinical development for r/r B-cell lymphomas
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cellectis (ADR) | $3.41 | −0.58% | $341.4M | — | — | 4.5 | −59.2% |
| Gilead Sciences | $139.30 | −4.36% | $180.87B | — | 16.0 | 5.9 | +10.2% |
| Autolus Therapeutics (ADR) | $2.34 | +0.43% | $622.8M | — | — | 5.3 | +118.4% |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| Caribou Biosciences | $1.65 | +2.17% | $160.7M | — | — | 16.0 | −43.8% |
| CRISPR Therapeutics | $57.50 | −0.35% | $5.57B | — | — | 415.7 | +1,041.4% |
| Median | 18.9 | 16.0 | 5.6 | +8.0% |